NextCure (NXTC) KOL event summary

Introduction and agenda

• Event focused on preliminary Phase 1 trial results for SIM0505, a CDH6-targeting ADC, presented at or following ASCO 2026, with a Q&A session and replay available.

• Agenda included SIM0505 overview, clinical data highlights, differentiation, unmet needs in gynecologic cancers, development plans, and closing remarks.

KOL background and credentials

• Speakers included Dr. Rakesh Dixit (ADC expert), Dr. Ursula Matulonis (Dana-Farber), Dr. Beryl Manning-Geist (Emory), Udayan Guha, MD, PhD (CMO), and other leading oncology experts.

Market insights and analysis

• Platinum-resistant ovarian cancer and uterine serous carcinoma have significant unmet needs, poor outcomes, and high mortality.

• Uterine serous carcinoma, though only 10% of uterine cancers, causes 40% of deaths; ovarian cancer is the fifth leading cause of cancer-related death among women.

• SIM0505 targets CDH6, highly expressed in multiple solid tumors, offering a promising therapeutic approach.

• Patient population in the trial was diverse, heavily pretreated, and representative of real-world demographics.